Tag: cardiovascular risk

1. Time spent cycling was associated with lower all-cause and cardiovascular disease-specific mortality in this multicenter European cohort study of patients with diabetes, independent of other exercise. 2. Taking up cycling over a five-year period was associated with lower mortality rates compared with those who did not cycle at all. Evidence...
1. The use of coronary artery calcium scoring was associated with significant improvements in the reclassification and discrimination of incident atherosclerotic cardiovascular disease. 2. Coronary artery calcium scoring may be beneficial as an adjunct to risk-enhancing factor assessment when identifying individuals at intermediate risk of atherosclerotic cardiovascular disease who would...
1. Clopidogrel monotherapy reduced long-term rates of all-cause mortality, non-fatal myocardial infarction, and stroke after drug-eluting stent placement compared with aspirin monotherapy. 2. The superiority of clopidogrel was seen for both thrombotic and bleeding endpoints and was consistent across demographic groups. Evidence Rating Level: 1 (Excellent)  Study Rundown: Patients who receive percutaneous...
1. Widespread diabetes screening helps to identify asymptomatic patients with preserved renal function and low diabetes-associated cardiovascular risk. 2. New cardiovascular risk stratification strategies are needed given heterogeneous characteristics of patients with type 2 diabetes.  Evidence Rating Level: 2 (Good)  Study Rundown: In the last decade, New Zealand Ministry of Health has...
1. Ziltivekimab lowered high-sensitivity CRP levels, a predictor of vascular events, compared to placebo in a dose-dependent manner. 2. Thrombotic biomarkers including fibrinogen, serum amyloid A, haptoglobin, secretory phospholipase A2, and lipoprotein were lower in treatment groups compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Prior studies, including the landmark...
1. Regardless of cardiovascular disease history and baseline blood pressure, a 5 mmHg reduction in systolic blood pressure reduced relative risk of major cardiovascular events by 10%. 2. These findings support considering antihypertensive medications for patients with increased cardiovascular risk, even those who are normotensive at baseline.  Evidence Rating Level: 1...
1. Patients without standard modifiable cardiovascular risk factors (SMuRFs) had a significantly higher all-cause mortality at 30 days after first presentation of STEMI. 2. Patients without SMuRFs were significantly less likely to receive statins, ACEIs, ARBs, or beta-blockers at discharge.  Evidence Rating Level: 2 (Good) Study Rundown: Standard modifiable cardiovascular risk factors...
1. Combined use of intracoronary near-infrared spectroscopy (NIRS) and intravascular ultrasound were effective at detecting untreated intracoronary lesions at high risk of major adverse cardiac event (MACE). 2. Highly lipidic lesions and large plaque burden were found to be independent predictors of non-culprit lesion-related MACEs. Evidence Rating Level: 2 (Good) Study Rundown:...
1. The use of long-term transdermal estrogen for castration therapy for prostate cancer showed no difference in cardiovascular events versus current standard of care. 2. Gynecomastia was significantly more common in the transdermal estrogen group than standard of care group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer, an ongoing major...
1. Patients who received low-dose colchicine daily had a ~30% lower risk of cardiovascular events compared to those who received placebo. 2. Although the incidence of cardiovascular death was similar between groups, the colchicine group had a numerically greater number of non-cardiovascular deaths as well as all-cause deaths compared to...